Targeting IL-17 and TH17 cells in chronic inflammation

By P. Miossec, J. Kolls. Nature reviews. Drug discovery, 2012

1,362 citations recorded by the source corpus.

Subfields: Dermatology, Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/13c560f74fb040023dd12dddba69af884ab2eba7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Dermatology

1. Gary S. Firestein
2. I. McInnes

In Hematology

1. Gary S. Firestein
2. I. McInnes

In Immunology

1. J. O’Shea
2. A. Garg
3. Nilesh Amatya
4. A. Laurence
5. Gary S. Firestein
6. I. McInnes
7. S. Gaffen
8. Eran Elinav

Citations in the corpus

• IL-17 Signaling: The Yin and the Yang (2017, background): “However, the efficacy of IL-17 blockade for other conditions has been less dramatic [7], though there are promising data from trials of ankylosing spondylitis and psoriatic arthritis [7, 12].”
• The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention (2015, background): “IL-17 acts on broadly expressed receptors to increase the production and recruitment of neutrophils to sites of inflammation and is especially important for host defense against Staphylococcus aureus and fungal infections (8).”
• Immunopathogenesis of rheumatoid arthritis (2017, positive): “Murine arthritis models strongly suggest a pivotal role for T helper 17 (Th17) cells (Miossec and Kolls, 2012; Lubberts, 2015).”
• Interaction between microbiota and immunity in health and disease (2020, background): “Of these cells, the Th17 subset is intensely studied because of its ambiguous roles in both host protection and inflammatory disorders.(109) The intestine harbors functionally distinct Th17 cell populations and their inflammatory propensity is largely determined by distinct bacteria eliciting their ”